Literature DB >> 3348977

Reversal of drug-resistance in multiple myeloma with verapamil.

B G Durie1, W S Dalton.   

Abstract

In vitro testing with a new doxorubicin resistant myeloma cell line revealed the reversal of drug resistance with as little as 100 ng/ml of verapamil (a calcium channel blocker), a dose easily achievable in humans. A first patient with IgG kappa myeloma is presented in whom resistance to VAD (vincristine/doxorubicin infusion plus dexamethasone) chemotherapy was reversed with the administration of verapamil. A subsequent clinical study has been initiated. The potential for further evaluation of calcium channel blockers in multiple myeloma is discussed.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3348977     DOI： 10.1111/j.1365-2141.1988.tb06190.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  12 in total

1.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells.

Authors:  A S Chong; P N Markham; H M Gebel; S D Bines; J S Coon
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 3.  Multiple myeloma. New treatment options.

Authors:  L Camba; B G Durie
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

4.  Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil.

Authors:  F W Busch; U Schmittele; G Ehninger
Journal:  Blut       Date:  1990-04

5.  Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Authors:  K Mross; K Hamm; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors.

Authors:  G Visani; M Fogli; P Tosi; E Ottaviani; B Gamberi; A Cenacchi; S Manfroi; S Tura
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

7.  Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells.

Authors:  Zhi-Wei Yu; Peng Zhao; Ming Liu; Xin-Shu Dong; Ji Tao; Xue-Qin Yao; Xin-Hua Yin; Yu Li; Song-Bin Fu
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

8.  Reversal of multidrug resistance by surfactants.

Authors:  D M Woodcock; M E Linsenmeyer; G Chojnowski; A B Kriegler; V Nink; L K Webster; W H Sawyer
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

9.  The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.

Authors:  G J Schuurhuis; H J Broxterman; H M Pinedo; T H van Heijningen; C K van Kalken; J B Vermorken; E C Spoelstra; J Lankelma
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

10.  Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance.

Authors:  I Judson; E Briasoulis; F Raynaud; J Hanwell; C Berry; H Lacey
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.